Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"A Phase 2, Open Label, Efficacy and Safety Study of Autologous HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

NCT06800404 is registered in ClinicalTrials.gov with Hope Biosciences Research Foundation as lead sponsor.

NCT NCT06800404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06800404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"A Phase 2, Open Label, Efficacy and Safety Study of Autologous HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
Lead sponsor
Hope Biosciences Research Foundation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 2, 2025
Completion date
January 31, 2027
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing remitting multiple sclerosis (rrms)